News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS Todd Neale April 03, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
Presentation ACC 2018 Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants Presenter: Steve Deitelzweig March 12, 2018
News Conference News ACC 2018 Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year Yael L. Maxwell March 11, 2018
News Conference News ACC 2016 Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding Todd Neale April 06, 2016
News Conference News ACC 2014 ARISTOTLE: Blood Pressure Adversely Affects Stroke Risk in A-fib Patients Caitlin E. Cox April 02, 2014
News Conference News ACC 2012 Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism L.A. McKeown March 26, 2012